Drugs / AK1967
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06331884 Comparator | Mar → Aug 2024 | — | 4TEEN4 Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT06832722 Comparator | Jul 2025 → Dec 2026 expected | cardiogenic shock | 4TEEN4 Pharmaceuticals GmbH | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK1967 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06331884 ↗ |
| Known as | Invobenitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06832722 ↗ |
| Known as | Procizumab | “DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)” NCT06331884 ↗1“AK1967 (Invobenitug also known as Procizumab)” NCT06832722 ↗ |
| Action | Inhibit | “DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)” NCT06331884 ↗ |
| Modality | Monoclonal antibody | “DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)” NCT06331884 ↗ |
| Route | Intravenous | “Escalating Single Intravenous Doses of AK1967 (Procizumab)” NCT06331884 ↗ |
| Target | DPP3 | “DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)” NCT06331884 ↗ |